Psychiatria pre prax 4/2022

Paliperidone extended-release and its use in the treatment of schizophrenia in daily clinical practice

Paliperidone (9-hydroxyrisperidone) is the primary active metabolite of risperidone and is used in treating schizophrenia and schizoaffective disorders. Despite their similarities, these two drugs have district pharmacokinetic and other biochemical characteristics that may results in differences in therapeutic efficacy and tolerability. Extended release oral paliperidone require less frequent dosing and produce more consistent plasma levels compared to risperidone. This short review of clinical pharmacology of oral paliperidone in comparison to risperidone is complemented by short case reports.

Keywords: schizophrenia, paliperidone, extended release, risperidone, clinical efficacy, tolerability and safety of drugs